Pharmaceutical Sector

Sun Pharma may acquire Zenotech Laboratories Ltd

Sun Pharma may acquire Zenotech Laboratories Ltd

Sun Pharma, which recently proposed a $4-billion deal to merge Ranbaxy Labs with itself, will also make an open offer to acquire around 28 per cent stake in Zenotech Laboratories Ltd.

In a regulatory filing, Sun Pharma said it could buy nearly 96 lakh shares of Hyderabad-based Zenotech, amounting to 28.1 per cent stake, for Rs 18.42 crore or Rs 19 per share. Ranbaxy owns 46.79 per cent stake in Zenotech.

The pharma giant added that the merger of Ranbaxy into it would result in Sun Pharma's indirectly acquiring Ranbaxy's 46.79 per cent voting rights over Zenotech.

EMA to inspect Ranbaxy's India unit

EMA to inspect Ranbaxy's India unit

Europe's drug regulator, the European Medicines Agency (EMA) has indicated that it is planning to inspect the Indian plants of generic drug maker Ranbaxy Laboratories.

Sun Pharma to acquire Ranbaxy in $3.2 billion all-share deal

Sun Pharma to acquire Ranbaxy in $3.2 billion all-share deal

Mumbai-based Sun Pharmaceutical Industries Ltd has confirmed that it will acquire beleaguered Ranbaxy Laboratories Ltd in a $3.2 billion all-stock deal.

Following its merger with Ranbaxy, Sun Pharma will become India's biggest pharmaceutical firm and the world's fifth biggest generic drugs maker.

FDA imposes import alert on Sun Pharma’s Gujarat facility

FDA imposes import alert on Sun Pharma’s Gujarat facility

Sun Pharmaceuticals Ltd has joined the list of top Indian drugmakers facing the heat of the Food & Drug Administration's annoyance as the U. S. regulator has imposed an import alert on its Karkhadi, Gujarat-based plant.

The drugmaker said in a statement that the Gujarat plant was a dedicated cephalosporin facility, and the import ban was a follow-up to an inspection of the facility by the FDA late last year. The regulator imposed the ban due to alleged non-compliance of current good manufacturing practice regulations.

Ranbaxy to recalls generic Lipitor in U.S

ranbaxy45454

Indian pharmaceutical giant, Ranbaxy has said that it has recalled more than 64,000 bottles of generic version of Lipitor in the US market after a suspected mix up of dose.

Ranbaxy Laboratories has announced its decision to recall more than 64,000 bottles of the generic versions of its cholesterol-lowering drug in the country. Several media reports have said that the company realised that a doze mix-up has affected the match. The decision to call comes after media reports said that

Natco Pharma shares hit record high after Delhi HC dismissed Teva suit

Natco Pharma shares hit record high after Delhi HC dismissed Teva suit

Stock in Hyderabad-based Natco Pharma Ltd hit a record high of Rs 876 apiece, up 4 per cent intraday on Monday, after the Delhi High Court dismissed a suit filed against the drug maker by Teva Pharmaceutical Industries Ltd.

Israel-based Teva Pharma had sought an injunction to prevent Natco from exporting blockbuster multiple sclerosis drug Copaxone, alleging that Natco's use in India of the well-known process to produce copolymer-1 breaches Yeda's Indian Patent No. 190759("IN'759").

But, the HC dismissed the plea, saying it was not within its jurisdiction.

Astrazeneca Pharma India shares jump 20% on delisting proposal

Astrazeneca Pharma India shares jump 20% on delisting proposal

Stock in AstraZeneca Pharma India jumped to its upper circuit filter of 20 per cent at Rs 1,113 a share in early morning trade on Monday on the National Stock Exchange (NSE) after the drug maker revealed its delisting plan.

AstraZeneca Pharma India's board will meet this Wednesday to discuss a proposal to delist the company's shares from the Indian stock exchanges.

The Indian drug maker received the proposal for delisting of its equity shares from the Indian stock exchanges from its Sweden-based parent firm AstraZeneca Pharmaceuticals AB.

Ranbaxy suspends shipments of APIs from its Toansa and Dewas plants

Ranbaxy suspends shipments of APIs from its Toansa and Dewas plants

Gurgaon-based drug maker Ranbaxy Laboratories Ltd on Tuesday announced that it had suspended all shipments of active pharmaceutical ingredients (APIs) from its Toansa and Dewas plants, which are currently banned from shipping products to the United States.

Ranbaxy voluntarily suspended shipments from the two plants in order to enable it to review processes and controls.

U.S., Indian health regulators will inform each other before conducting inspections

U.S., Indian health regulators will inform each other before conducting inspecti

U. S. Food & Drug Administration (USFDA) Commissioner Margaret A Hamburg on Monday signed an agreement with India's Union Health Minister Ghulam Nabi Azad under which regulators from the two countries will inform the regulatory authorities of each other before conducting inspections.

Under the terms of the agreement, health inspectors of the host-country may join inspections as observers. The two countries also agreed to exchange information relevant to any lack of compliance with accepted good manufacturing practices (GMP) etc.

Aurobindo Pharma reports over four-fold rise in Q3 consolidated net; shares jump

Aurobindo Pharma reports over four-fold rise in Q3 consolidated net; shares jump

Aurobindo Pharma jumped nearly 6 per cent in morning trade on Friday after the drug-maker announced an over four-fold jump in its quarterly consolidated net profit.

The company announced that its consolidated net profit jumped more than 400 per cent to Rs 417 crore in the three months ended December 31, 2013. In the corresponding period of the previous year, the company had pocketed a consolidated net profit of Rs 92 crore.